Augmented Renal Clearance in Neurocritical Care Population: A Prospective Multicenter Study

What this Trial Is About

Stroke, severe brain injury, status epilepticus, and meningitis are serious neurological illnesses that often lead to seizures and infections, causing poor patient outcomes if not treated properly. This research focuses on a condition called augmented renal clearance (ARC), where kidney function is enhanced, affecting how medications are cleared from the body. The study aims to better understand ARC in patients with life-threatening neurological illnesses to improve medication dosing and treatment success. The study is a multicenter prospective observational design involving adult patients admitted to Neuroscience Intensive Care Units with severe neurological conditions like intracerebral hemorrhage, subarachnoid hemorrhage, ischemic stroke, status epilepticus, meningitis, and traumatic brain injury. Participants will have their kidney function measured daily through urine collection for up to 10 days or until ICU discharge. Blood samples will be collected from patients receiving certain anti-seizure and antibiotic medications to measure drug levels and suggest dose adjustments for those with ARC. During the study, researchers will collect urine and blood samples to detect ARC and its contributing factors. They will track kidney clearance and drug concentrations during hospital stays. The primary measures include creatinine clearance over 10 days or until ICU discharge and drug concentration after consistent dosing. This work aims to provide guidelines for identifying ARC and optimizing medication dosing to improve outcomes for patients with critical neurological illnesses.

Augmented Renal Clearance in Neurocritical Care